MX2019006098A - Ensayo de anticuerpos. - Google Patents
Ensayo de anticuerpos.Info
- Publication number
- MX2019006098A MX2019006098A MX2019006098A MX2019006098A MX2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A
- Authority
- MX
- Mexico
- Prior art keywords
- test sample
- liver cancer
- mammalian subject
- antibody
- detecting
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un método para detectar cáncer de hígado en un sujeto mamífero mediante la detección de un anticuerpo en una muestra de prueba que comprende un fluido corporal del sujeto mamífero, en el que el anticuerpo es un autoanticuerpo inmunológicamente específico para una proteína marcadora de tumores seleccionada del grupo que consiste en de MMP9, AIF1, EpCAM y CDKN1B, tal método comprende poner en contacto la muestra de prueba con un antígeno marcador de tumores seleccionado del grupo que consiste en MMP9, AIF1, EpCAM y CDKN1B y determinar la presencia o ausencia de complejos del antígeno marcador de tumores unido a autoanticuerpos presente en la muestra de prueba donde la presencia de dichos complejos es indicativa de la presencia de cáncer de hígado. También se incluyen dentro de la invención métodos correspondientes para diagnosticar y tratar el cáncer de hígado en un sujeto mamífero, métodos correspondientes para predecir la respuesta a un tratamiento contra el cáncer de hígado, un método correspondiente para detectar un anticuerpo en una muestra de prueba que comprende un fluido corporal de un sujeto mamífero y kits adecuados para implementar los métodos de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619954.9A GB201619954D0 (en) | 2016-11-25 | 2016-11-25 | Antibody assay |
| PCT/GB2017/053541 WO2018096351A1 (en) | 2016-11-25 | 2017-11-24 | Antibody assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006098A true MX2019006098A (es) | 2019-12-02 |
Family
ID=58073509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006098A MX2019006098A (es) | 2016-11-25 | 2017-11-24 | Ensayo de anticuerpos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190376975A1 (es) |
| EP (1) | EP3545309B1 (es) |
| JP (1) | JP7249284B2 (es) |
| KR (1) | KR20190088510A (es) |
| CN (2) | CN108107218B (es) |
| AU (1) | AU2017365931A1 (es) |
| BR (1) | BR112019010636A2 (es) |
| CA (1) | CA3044492A1 (es) |
| GB (1) | GB201619954D0 (es) |
| IL (1) | IL266857A (es) |
| MX (1) | MX2019006098A (es) |
| RU (1) | RU2769987C2 (es) |
| WO (1) | WO2018096351A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109116023B (zh) * | 2018-06-14 | 2021-06-04 | 郑州大学第一附属医院 | 一种肺癌标志物抗-mmp12自身抗体及其应用 |
| CN109709335B (zh) * | 2018-12-18 | 2020-10-27 | 中国医学科学院基础医学研究所 | 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用 |
| CN109633165B (zh) * | 2018-12-18 | 2021-03-09 | 中国医学科学院基础医学研究所 | 抗hspa4自身抗体作为乳腺癌诊断或预后评估标志物的应用 |
| CN110579611B (zh) * | 2019-09-18 | 2023-01-31 | 郑州大学 | 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法 |
| JPWO2022118947A1 (es) * | 2020-12-04 | 2022-06-09 | ||
| CN114994318A (zh) * | 2022-06-16 | 2022-09-02 | 深圳上泰生物工程有限公司 | 一种用于检测akr1b10的试剂盒及其制备方法 |
| CN116444680B (zh) * | 2022-12-28 | 2024-05-03 | 杭州凯保罗生物科技有限公司 | 一种ralgds-krt8-aif1融合肿瘤抗原蛋白的制备方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7387881B2 (en) * | 2001-09-19 | 2008-06-17 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the liver |
| ITPD20030264A1 (it) * | 2003-10-30 | 2005-04-30 | Xeptagen Spa | Metodo di diagnosi altamente specifico per neoplasie |
| TWI281473B (en) * | 2003-12-19 | 2007-05-21 | Ind Tech Res Inst | Biomarkers for liver diseases and method for using same |
| EP2074422A4 (en) * | 2006-11-13 | 2010-02-17 | Life Technologies Corp | METHOD AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS |
| RU2505821C2 (ru) * | 2008-12-02 | 2014-01-27 | Индастриал Текнолоджи Ресерч Институт | Биомаркеры, пригодные при диагностике фиброза печени |
| US20120309034A1 (en) * | 2010-02-12 | 2012-12-06 | Nitto Boseki Co., Ltd. | METHOD FOR MEASURING IMMUNITY OF COMPLEX OF Ku86 AND AUTOANTIBODY THEREOF, KIT USED THEREFOR, AND METHOD FOR DETERMINING CANCER USING SAME |
| CN102175864A (zh) * | 2011-01-19 | 2011-09-07 | 江苏永鼎股份有限公司 | 一组早期肝癌分子标志物及其应用 |
| EP2875356A1 (en) * | 2012-07-23 | 2015-05-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method for diagnosing scleroderma |
| JP2014240771A (ja) * | 2013-06-11 | 2014-12-25 | 日東紡績株式会社 | Ｋｕ７０／Ｋｕ８６ヘテロダイマーに対する自己抗体の免疫測定方法、それに用いるキットおよびそれを用いた癌判定方法 |
| GB201320061D0 (en) * | 2013-11-13 | 2013-12-25 | Electrophoretics Ltd | Materials nad methods for diagnosis and prognosis of liver cancer |
| GB201411060D0 (en) * | 2014-06-20 | 2014-08-06 | Oncimmune Ltd | Improved immunoassay method |
-
2016
- 2016-11-25 GB GBGB1619954.9A patent/GB201619954D0/en not_active Ceased
-
2017
- 2017-11-24 AU AU2017365931A patent/AU2017365931A1/en not_active Abandoned
- 2017-11-24 JP JP2019548777A patent/JP7249284B2/ja active Active
- 2017-11-24 CA CA3044492A patent/CA3044492A1/en not_active Abandoned
- 2017-11-24 WO PCT/GB2017/053541 patent/WO2018096351A1/en unknown
- 2017-11-24 MX MX2019006098A patent/MX2019006098A/es unknown
- 2017-11-24 RU RU2019118625A patent/RU2769987C2/ru active
- 2017-11-24 US US16/463,549 patent/US20190376975A1/en active Pending
- 2017-11-24 EP EP17807913.3A patent/EP3545309B1/en active Active
- 2017-11-24 BR BR112019010636A patent/BR112019010636A2/pt unknown
- 2017-11-24 KR KR1020197018129A patent/KR20190088510A/ko active Search and Examination
- 2017-11-27 CN CN201711213227.4A patent/CN108107218B/zh active Active
- 2017-11-27 CN CN202110715736.7A patent/CN113655224A/zh active Pending
-
2019
- 2019-05-23 IL IL266857A patent/IL266857A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201619954D0 (en) | 2017-01-11 |
| CN108107218A (zh) | 2018-06-01 |
| BR112019010636A2 (pt) | 2019-10-01 |
| US20190376975A1 (en) | 2019-12-12 |
| JP2020515826A (ja) | 2020-05-28 |
| CN108107218B (zh) | 2021-10-08 |
| RU2019118625A (ru) | 2020-12-25 |
| EP3545309B1 (en) | 2021-03-31 |
| RU2019118625A3 (es) | 2021-03-31 |
| CA3044492A1 (en) | 2018-05-31 |
| KR20190088510A (ko) | 2019-07-26 |
| EP3545309A1 (en) | 2019-10-02 |
| AU2017365931A1 (en) | 2019-06-06 |
| RU2769987C2 (ru) | 2022-04-12 |
| JP7249284B2 (ja) | 2023-03-30 |
| CN113655224A (zh) | 2021-11-16 |
| IL266857A (en) | 2019-07-31 |
| WO2018096351A1 (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006098A (es) | Ensayo de anticuerpos. | |
| MX2020009021A (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco. | |
| MX2014001377A (es) | Metodo para detectar cancer pancreatico. | |
| JO3812B1 (ar) | أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1) | |
| MX344053B (es) | Metodos para determinar isotipos de anticuerpos anti-farmacos. | |
| EA201370063A1 (ru) | Фосфолипидом рака | |
| CY1119972T1 (el) | Προσδιορισμος για αντισωματα ιου jc | |
| NZ706187A (en) | Assays for the detection of anti-tnf drugs and autoantibodies | |
| NZ609824A (en) | Immunochromatography devices, methods and kits | |
| NZ629074A (en) | Biomarkers for gastric cancer and uses thereof | |
| PH12020551371A1 (en) | Assays to detect neurodegeneration | |
| AR103935A1 (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2 | |
| MX2019008911A (es) | Metodos, matrices y usos de estos. | |
| BR112016007037A2 (pt) | método para detectar câncer pancreático, anticorpo monoclonal e kit | |
| MX369610B (es) | Metodos, dispositivos y sistemas para analisis de muestras. | |
| WO2019089858A3 (en) | Methods of assessing or monitoring a response to a cell therapy | |
| EA201400571A1 (ru) | Специфичные к трансресвератролу антитела и их применение | |
| MX2022013738A (es) | Ensayo de anticuerpos neutralizantes para proteinas terapeuticas. | |
| EP4253950A3 (en) | Ce-western applications for antibody development | |
| MX2016017048A (es) | Inmunoensayo reactivo y colaborativo potenciado por enzimas (ceer) usando citometria de flujo. | |
| MX2014011849A (es) | Reactivos, procedimientos y kits para la clasificación del cáncer. | |
| MX2018015047A (es) | Metodo para la deteccion de un anticuerpo igm especifico para un flavivirus en una muestra. | |
| WO2018226098A3 (en) | METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF | |
| WO2020251916A8 (en) | Reagents and methods for cancer detection, prognosis, and therapeutic monitoring | |
| JP2017201255A5 (es) |